<DOC>
	<DOC>NCT02486640</DOC>
	<brief_summary>This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon</brief_summary>
	<brief_title>Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>Patients with the diagnosis of relapsing remitting multiple sclerosis or a clinically isolated syndrome. Patients must be on treatment with Betaferon or the decision to treat patients with Betaferon has been made by the attending physician. Patients must be using the BETACONNECTTM autoinjector for Betaferon application. Written informed consent must be obtained. Patients receiving any other disease modifying drug. Contraindications of Betaferon described in the Summary of Product Characteristics. Patients participating in any other clinical or noninterventional study, evaluating MS therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>RRMS, CIS</keyword>
</DOC>